443 related articles for article (PubMed ID: 21787828)
21. Natural immunization against malaria: causal prophylaxis with antibiotics.
Friesen J; Silvie O; Putrianti ED; Hafalla JC; Matuschewski K; Borrmann S
Sci Transl Med; 2010 Jul; 2(40):40ra49. PubMed ID: 20630856
[TBL] [Abstract][Full Text] [Related]
22. Addition of histamine to subcutaneously injected Plasmodium berghei sporozoites increases the parasite liver load and could facilitate whole-parasite vaccination.
Pfeil J; Heine JF; Mueller AK
Malar J; 2015 Jan; 14():36. PubMed ID: 25627880
[TBL] [Abstract][Full Text] [Related]
23. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites.
Butler NS; Schmidt NW; Vaughan AM; Aly AS; Kappe SH; Harty JT
Cell Host Microbe; 2011 Jun; 9(6):451-62. PubMed ID: 21669394
[TBL] [Abstract][Full Text] [Related]
24. Whole parasite vaccination approaches for prevention of malaria infection.
Butler NS; Vaughan AM; Harty JT; Kappe SH
Trends Immunol; 2012 May; 33(5):247-54. PubMed ID: 22405559
[TBL] [Abstract][Full Text] [Related]
25. Protection against malaria by immunization with non-attenuated sporozoites under single-dose piperaquine-tetraphosphate chemoprophylaxis.
Pfeil J; Sepp KJ; Heiss K; Meister M; Mueller AK; Borrmann S
Vaccine; 2014 Oct; 32(45):6005-11. PubMed ID: 25203450
[TBL] [Abstract][Full Text] [Related]
26. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice.
Aly AS; Downie MJ; Mamoun CB; Kappe SH
Cell Microbiol; 2010 Jul; 12(7):930-8. PubMed ID: 20088947
[TBL] [Abstract][Full Text] [Related]
27. The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review.
Epstein JE; Richie TL
Curr Opin Infect Dis; 2013 Oct; 26(5):420-8. PubMed ID: 23982233
[TBL] [Abstract][Full Text] [Related]
28. An early commitment to expression of a particular TCRVbeta chain on CD8(+) T cells responding to attenuated Plasmodium berghei sporozoites is maintained following challenge with infectious sporozoites.
Lumsden JM; Cranmer MA; Krzych U
Parasite Immunol; 2010; 32(9-10):644-55. PubMed ID: 20691016
[TBL] [Abstract][Full Text] [Related]
29. A whole parasite vaccine to control the blood stages of Plasmodium: the case for lateral thinking.
Good MF
Trends Parasitol; 2011 Aug; 27(8):335-40. PubMed ID: 21514227
[TBL] [Abstract][Full Text] [Related]
30. Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection.
Peng X; Keitany GJ; Vignali M; Chen L; Gibson C; Choi K; Huang F; Wang R
J Immunol; 2014 Aug; 193(3):1268-77. PubMed ID: 24958899
[TBL] [Abstract][Full Text] [Related]
31. Protective and pathogenic roles of CD8+ T cells during malaria infection.
Hafalla JC; Cockburn IA; Zavala F
Parasite Immunol; 2006; 28(1-2):15-24. PubMed ID: 16438672
[TBL] [Abstract][Full Text] [Related]
32. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
Reyes-Sandoval A; Sridhar S; Berthoud T; Moore AC; Harty JT; Gilbert SC; Gao G; Ertl HC; Wilson JC; Hill AV
Eur J Immunol; 2008 Mar; 38(3):732-41. PubMed ID: 18266272
[TBL] [Abstract][Full Text] [Related]
33. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites.
Meraldi V; Romero JF; Kensil C; Corradin G
Vaccine; 2005 Apr; 23(21):2801-12. PubMed ID: 15780728
[TBL] [Abstract][Full Text] [Related]
34. Medicine: knockout malaria vaccine?
Ménard R
Nature; 2005 Jan; 433(7022):113-4. PubMed ID: 15650722
[No Abstract] [Full Text] [Related]
35. Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria.
Tartz S; Kamanova J; Simsova M; Sebo P; Bolte S; Heussler V; Fleischer B; Jacobs T
Infect Immun; 2006 Apr; 74(4):2277-85. PubMed ID: 16552058
[TBL] [Abstract][Full Text] [Related]
36. Preerythrocytic malaria vaccine development.
Mikolajczak SA; Aly AS; Kappe SH
Curr Opin Infect Dis; 2007 Oct; 20(5):461-6. PubMed ID: 17762778
[TBL] [Abstract][Full Text] [Related]
37. Protective efficacy and safety of liver stage attenuated malaria parasites.
Kumar H; Sattler JM; Singer M; Heiss K; Reinig M; Hammerschmidt-Kamper C; Heussler V; Mueller AK; Frischknecht F
Sci Rep; 2016 May; 6():26824. PubMed ID: 27241521
[TBL] [Abstract][Full Text] [Related]
38. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.
Bergmann-Leitner ES; Legler PM; Savranskaya T; Ockenhouse CF; Angov E
Vaccine; 2011 Aug; 29(35):5940-9. PubMed ID: 21722682
[TBL] [Abstract][Full Text] [Related]
39. A Sporozoite- and Liver Stage-expressed Tryptophan-rich Protein Plays an Auxiliary Role in Plasmodium Liver Stage Development and Is a Potential Vaccine Candidate.
Jaijyan DK; Singh H; Singh AP
J Biol Chem; 2015 Aug; 290(32):19496-511. PubMed ID: 25960542
[TBL] [Abstract][Full Text] [Related]
40. Plasmodium berghei circumsporozoite protein encapsulated in oligomannose-coated liposomes confers protection against sporozoite infection in mice.
Terkawi MA; Kuroda Y; Fukumoto S; Tanaka S; Kojima N; Nishikawa Y
Malar J; 2014 Nov; 13():426. PubMed ID: 25373617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
